- Previous Close
1.1100 - Open
1.1300 - Bid 1.0700 x 100
- Ask 1.1600 x 100
- Day's Range
1.0469 - 1.1700 - 52 Week Range
0.7300 - 2.0900 - Volume
52,908 - Avg. Volume
66,221 - Market Cap (intraday)
28.049M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5900 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
acceleratediagnostics.comRecent News: AXDX
View MorePerformance Overview: AXDX
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXDX
View MoreValuation Measures
Market Cap
28.05M
Enterprise Value
66.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.94
Price/Book (mrq)
--
Enterprise Value/Revenue
5.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-75.85%
Return on Equity (ttm)
--
Revenue (ttm)
12.23M
Net Income Avi to Common (ttm)
-37.91M
Diluted EPS (ttm)
-2.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
9.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-54.67M